Seminars in Hematology
Volume 44 , Pages S18-S21 , July 2007

New Agents in Development for Non-Hodgkin’s Lymphoma

References 

  1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  2. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927–1932
  3. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–324
  4. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–3143
  5. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195
  6. Friedberg JW, Huang J, Dillon H, et al. Initial therpeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). Proc Am Soc Clin Oncol. 2006;24:428s;(abstr 7527)
  7. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143–4149
  8. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23:7565–7573
  9. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800
  10. Hagenbeek A, Plesner T, Walewski J, et al. HuMax-CD20 fully human monoclonal antibody in follicular lymphoma (First human exposure: Early results of an ongoing phase I/II trial). Blood. 2004;104:404a;(abstr 1400)
  11. Coiffier B, Tilly H, Pedersen IM, et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia (Early results from an ongoing phase I/II clinical trial). Blood. 2005;106:135a;(abstr 448)
  12. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res. 2004;10:2868–2878
  13. Morschhauser F, Leonard JP, Fayad L, et al. Rituximab-relapsing patients with non-Hodgkins lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20): Phase I/II results. Blood. 2006;108:769a
  14. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol. 1995;32:1413–1427
  15. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: Phase I/II clinical trial results. Clin Cancer Res. 2004;10:5327–5334
  16. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: A CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–1814
  17. Fayad L, Patel H, Verhoef G, et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood. 2006;108:766a;(abstr 2711)
  18. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005;23:4390–4398
  19. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. 1999;11:203–210
  20. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2001;2:203–209
  21. Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood. 1997;90:4297–4306
  22. Vyth-Dreese FA, Boot H, Dellemijn TA, et al. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin’s lymphoma. Immunology. 1998;94:580–586
  23. Advani R, Forero-Torres A, Furman R, et al. SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin’s lymphoma: Evidence of antitumor activity from a phase I study. Blood. 2006;108:209a;(abstr 695)
  24. Khan KD, Emmanouilides C, Benson DM, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res. 2006;12:7046–7053
  25. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:5044–5051
  26. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:3880–3886
  27. Leonard JP, Friedberg JW, Younes A, et al. Results from a phase I/II study of galiximab (anti-CD80) in combination with rituximab (anti-CD20) for relapsed or refractory, follicular NHL. Ann Oncol. 2005;16:v71
  28. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548–551
  29. Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212–219
  30. Singh H, Serrano LMA, Olivares S, et al. Combining immunocytokine with adoptive immunotherapy to treat B-lineage lymphomas. Blood. 2005;106:104a;(abstr 343)
  31. Weng W-K, Stavenhagen J, Koenig S, Levy R. Rituximab variants with re-engineered Fc with higher affinity to activating FcgR eliminate the functional difference between FcgR genotypes. Blood. 2005;106:105a;(abstr 347)
  32. Weiner GJ, Bowles JA, Link BK, et al. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2005;106:106a;(abstr 348)

PII: S0037-1963(07)00096-0

doi: 10.1053/j.seminhematol.2007.06.005

Seminars in Hematology
Volume 44 , Pages S18-S21 , July 2007

Article Tools